Nice succinct status summary of the various Covid-
Post# of 714
(Total Views: 457)
Posted On: 10/28/2020 4:44:06 PM
Nice succinct status summary of the various Covid-19 vaccine programs in the morning brew. When was the last time you read something succinct?
I can't post a link to the source material, as this was in an email. BUT, to subscribe (free) to the Brew, use this link:
morningbrew.com/daily/r/?kid=49bfd9
Quote:
AstraZeneca: Better than it was. We had suspended our late-stage vaccine trial after a participant developed neurological symptoms. But this week we restarted it when independent monitoring committees and international regulators agreed that it was safe to resume.
Johnson & Johnson: Same here; we’re back up and running after a reported stroke incident in a volunteer. Outside experts and the FDA sniffed around and said we’re good to go.
FYI, our vaccine is the only one being tested that involves a single dose.
Pfizer: Optimistic. The current trial with BioNTech could reveal our vaccine's effectiveness by late November, which would be the first from any vaccine candidate. We could potentially get emergency authorization by the end of the year.
Still, we just barely beat Q3 earnings estimates yesterday. Our costs were down, but sales fell 4% thanks to people’s continued reluctance to go to the doctor—i.e. fewer prescriptions for our drugs. It’s not just us; they’re having the same problem over at Eli Lilly.
Herd immunity: Stock is down. Doctors don’t know yet if antibodies = immunity, but it may not matter. A study published Monday showed the number of people with antibodies dropped significantly (27%) in a three-month period, indicating that any immunity could be temporary.
The study hasn’t been peer reviewed yet.
Big picture: The U.S.’ vaccine game is high-stakes. Any slip-ups in the program—such as only four out of six candidates proving effective, or not enough people getting vaccinated—could mean we’ll be dealing with the virus well into 2023. But if everything goes smoothly, we could turn the tide by July of next year.
+ FYI: On Monday, Dr. Anthony Fauci told Yahoo Finance that the “primary endpoint” of a vaccine is “to prevent clinically recognizable disease,” aka stamping out symptoms, rather than eliminating the virus entirely.
I can't post a link to the source material, as this was in an email. BUT, to subscribe (free) to the Brew, use this link:
morningbrew.com/daily/r/?kid=49bfd9
(1)
(0)Scroll down for more posts ▼